Table 1.
Baseline characteristics of the 38 included patients staged using 68Ga-PSMAHBED-CC conjugate 11 ligand PET/MRI(CT) before 177Lu-PSMA-617 radioligand therapy
| Characteristic | Value |
|---|---|
| Age (years), median (IQR) | 71.47 (67.30, 77.34) |
| Prior radical prostatectomy, n (%) | 28 (73.7) |
| Prior primary radiotherapy, n (%) | 5 (13.2) |
| Prior systemic therapy lines, n (%) | |
| ≤ 2 | 11 (29) |
| ≥ 3 | 27 (71) |
| ADT at imaging, n (%) | 25 (65.8) |
| PET/CT, n (%) | 6 (15.8) |
| PET/MRI, n (%) | 32 (84.2) |
| Amount of used PSMA (MBq), median (IQR) | 171.50 (160.75, 187.25) |
| Metastatic sites, n (%) | |
| Local recurrence | 11 (28.9) |
| Lymph nodes | 30 (78.9) |
| Bone | 30 (78.9) |
| Viscera | 6 (15.8) |
| Prostate-specific antigen (ng/ml), median (IQR) | 60.8 (15.4, 264.2). |
| Hemoglobin (mg/dl), median (IQR) | 11.8 (10.6, 13.2) |
| C-reactive protein (g/dl), median (IQR) | 0.4 (0.2, 1.2) |
| Lactate dehydrogenase (U/L), median (IQR) | 189.0 (172.0, 245.3) |
| Alkaline phosphatase (U/L), median (IQR) | 68.0 (56.5, 123.3) |
IQR interquartile range, ADT androgen-deprivation therapy, PSA prostate-specific antigen